GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (NYSE:TAK) » Definitions » Cyclically Adjusted PS Ratio

Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Cyclically Adjusted PS Ratio : 1.54 (As of Apr. 29, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Takeda Pharmaceutical Co Cyclically Adjusted PS Ratio?

As of today (2024-04-29), Takeda Pharmaceutical Co's current share price is $13.17. Takeda Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $8.55. Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio for today is 1.54.

The historical rank and industry rank for Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio or its related term are showing as below:

TAK' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.34   Med: 1.85   Max: 3.13
Current: 1.68

During the past years, Takeda Pharmaceutical Co's highest Cyclically Adjusted PS Ratio was 3.13. The lowest was 1.34. And the median was 1.85.

TAK's Cyclically Adjusted PS Ratio is ranked better than
57.78% of 739 companies
in the Drug Manufacturers industry
Industry Median: 2.09 vs TAK: 1.68

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Takeda Pharmaceutical Co's adjusted revenue per share data for the three months ended in Dec. 2023 was $2.428. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $8.55 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Takeda Pharmaceutical Co Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Cyclically Adjusted PS Ratio Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.10 1.52 1.82 1.56 1.85

Takeda Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.76 1.85 1.90 1.93 1.67

Competitive Comparison of Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.



Takeda Pharmaceutical Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=13.17/8.55
=1.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takeda Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Takeda Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=2.428/106.8000*106.8000
=2.428

Current CPI (Dec. 2023) = 106.8000.

Takeda Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 2.502 95.700 2.792
201406 2.555 98.000 2.784
201409 2.602 98.500 2.821
201412 2.599 97.900 2.835
201503 2.313 97.900 2.523
201506 2.283 98.400 2.478
201509 2.410 98.500 2.613
201512 2.545 98.100 2.771
201603 2.340 97.900 2.553
201606 2.623 98.100 2.856
201609 2.613 98.000 2.848
201612 2.555 98.400 2.773
201703 2.338 98.100 2.545
201706 2.573 98.500 2.790
201709 2.488 98.800 2.689
201712 2.748 99.400 2.953
201803 2.396 99.200 2.580
201806 2.598 99.200 2.797
201809 2.439 99.900 2.607
201812 2.823 99.700 3.024
201903 2.075 99.700 2.223
201906 2.517 99.800 2.694
201909 2.414 100.100 2.576
201912 2.528 100.500 2.686
202003 2.278 100.300 2.426
202006 2.380 99.900 2.544
202009 2.375 99.900 2.539
202012 2.558 99.300 2.751
202103 2.250 99.900 2.405
202106 2.774 99.500 2.978
202109 2.426 100.100 2.588
202112 2.514 100.100 2.682
202203 2.337 101.100 2.469
202206 2.335 101.800 2.450
202209 2.237 103.100 2.317
202212 2.588 104.100 2.655
202303 2.258 104.400 2.310
202306 2.393 105.200 2.429
202309 2.254 106.200 2.267
202312 2.428 106.800 2.428

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Takeda Pharmaceutical Co  (NYSE:TAK) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Takeda Pharmaceutical Co Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Business Description

Address
1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Headlines

From GuruFocus